View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 1, 2021

Low awareness of rare diseases increases morbidity and potential mortality

Lack of awareness around rare diseases patients, physicians and the public makes it harder to identify symptoms and receive available treatments.

By GlobalData Healthcare

Orphan or rare diseases are conditions that affect a small percentage of the population in a given country. The widely accepted definition in the US is a disease that affects fewer than 200,000 people nationwide. According to the European Commission on Public Health, a rare disease refers to a condition that affects fewer than one in 2,000 people.

More than 7,000 individual rare diseases have been characterised by scientists around the world. According to Global Genes, a US-based non-profit advocacy group for people with rare diseases, an estimated 300 million people worldwide live with one of the 7,000 diseases that are recognised as rare conditions within the US.

The overwhelming majority of rare diseases are caused by genetic defects. This provides a significant opportunity for therapeutics such as monoclonal antibodies, gene therapies, and stem cell therapies, which can effectively manage diseases that lead to life-threatening consequences such as immune deficiency and neuromuscular dysfunction.

There are substantial challenges when it comes to developing drugs for rare diseases. The rarity of these diseases creates challenges for clinical trial recruitment, and funding for research into orphan diseases is challenging to secure. According to the Rare Genomics Institute, a non-profit advocacy group based in the US, around 400 orphan diseases can be treated with pharmacotherapy. This is far below the number of rare diseases that have been characterised, which means that there is ample opportunity for pharmaceutical companies to develop therapies that address the needs of millions of people in this underserved patient population.

Despite the well-understood challenges of developing therapies for orphan diseases, another obstacle is low disease awareness among patients, physicians and members of the general public. Lack of awareness reduces a physician’s ability to accurately detect symptoms and a patient’s ability to gain access to treatment when therapies are available. Examples of rare diseases that can be treated include acromegaly, posterior uveitis and myasthenia gravis. All three of these conditions have symptoms that are either subtle or general in nature, which introduces challenges with diagnosis and subsequent disease management.

Initiatives to raise awareness have been able to help susceptible individuals identify risk factors or undergo genetic testing. This is not always sufficient, however, and many people remain unaware of their risk of suffering from a rare disease over the course of their lifetime. As such, patients can experience significant morbidity for many years before receiving an accurate diagnosis. Late diagnosis is a risk factor for increased mortality when a disease that affects multiple organ systems remains untreated for a long period of time.

It is critically important that interactions between medical professionals and the general public are optimised so that people feel able to approach their doctor with health concerns, undergo clinical assessments and begin any necessary treatments to reduce their risk of long-term morbidity and a needlessly reduced life expectancy.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy